NAMPT-SIRT1 Axis as Master Regulator of SASP-Dependent Complement Amplification

Target: NAMPT, SIRT1 Composite Score: 0.592 Price: $0.59▲0.2% Citation Quality: Pending neurodegeneration Status: promoted

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

📄 Export → LaTeX

Select venue

arXiv Preprint NeurIPS Nature Methods PLOS ONE

🌐 Open in Overleaf →

📖 Export BibTeX

🔥 Neuroinflammation 🧠 Neurodegeneration

✓ All Quality Gates Passed

Evidence Strength Pending (0%)

Citations

Debates

Supporting

Opposing

Quality Report Card click to collapse

C+

Composite: 0.592

Top 45% of 1875 hypotheses

T5 Contested

Contradicted by evidence, under dispute

B+ Mech. Plausibility 15% 0.70 Top 35%

B Evidence Strength 15% 0.60 Top 37%

B+ Novelty 12% 0.75 Top 32%

B Feasibility 12% 0.65 Top 45%

B Impact 12% 0.68 Top 58%

B Druggability 10% 0.60 Top 42%

C+ Safety Profile 8% 0.55 Top 47%

B+ Competition 6% 0.70 Top 36%

A Data Availability 5% 0.80 Top 20%

B Reproducibility 5% 0.65 Top 36%

Evidence

5 supporting | 4 opposing

Citation quality: 0%

Debates

1 session B

Avg quality: 0.65

Convergence

0.00 F 30 related hypothesis share this target

From Analysis:

test

test

→ View full analysis & debate transcript

Description

Mechanistic Overview

...

Mechanistic Overview

NAMPT-SIRT1 Axis as Master Regulator of SASP-Dependent Complement Amplification starts from the claim that modulating NAMPT, SIRT1 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview NAMPT-SIRT1 Axis as Master Regulator of SASP-Dependent Complement Amplification starts from the claim that modulating NAMPT, SIRT1 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview NAMPT-SIRT1 Axis as Master Regulator of SASP-Dependent Complement Amplification starts from the claim that Targeting the NAMPT-NAD+-SIRT1 Axis to Disrupt SASP-Mediated Complement Cascade Amplification. The NAMPT-mediated NAD+ salvage pathway directly controls SIRT1 deacetylase activity, which in turn regulates NFKB1 acetylation status and downstream SASP cytokine production including IL1B. By enhancing NAMPT activity or SIRT1 function, we can suppress the SASP-driven complement C1Q/C3 amplification that mediates synaptic loss. Framed more explicitly, the hypothesis centers NAMPT, SIRT1 within the broader disease setting of neurodegeneration. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating NAMPT, SIRT1 or the surrounding pathway space around not yet explicitly specified can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.60, novelty 0.75, feasibility 0.65, impact 0.68, mechanistic plausibility 0.70, and clinical relevance 0.00. ## Molecular and Cellular Rationale The nominated target genes are `NAMPT, SIRT1` and the pathway label is `not yet explicitly specified`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific. Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of NAMPT, SIRT1 or not yet explicitly specified is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. NAMPT-mediated NAD+ salvage pathways are critical for neuronal bioenergetics and protection after injury. Identifier 31553812. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. Ablation of NAMPT in dopaminergic neurons leads to neurodegeneration. Identifier 39489186. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage. Identifier 25215490. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 4. TREM2 receptor protects against complement-mediated synaptic loss by binding to complement C1Q. Identifier 37442133. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 5. Sirtuin-NAD Activator trial in AD (NCT05040321) using MIB-626 provides pathway-specific human validation. Identifier NCT05040321. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. SIRT1 has context-dependent roles in neuroinflammation, with some studies showing that excessive SIRT1 activation can impair protective immune responses. Identifier 27235851. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. NAMPT inhibitors are being explored as anticancer strategies, highlighting the pathway's role in cellular proliferation. Identifier 27235851. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 3. SIRT1 activators including resveratrol have failed to demonstrate consistent efficacy in human neurodegenerative disease trials. Identifier 27235851. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 4. NAMPT (visfastin) is elevated in metabolic syndrome and inflammation - raising question of whether enhancing already dysregulated pathway is optimal. Identifier 27235851. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.595`, debate count `1`, citations `9`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. 1. Trial context: ACTIVE_NOT_RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates NAMPT, SIRT1 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "NAMPT-SIRT1 Axis as Master Regulator of SASP-Dependent Complement Amplification". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting NAMPT, SIRT1 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers NAMPT, SIRT1 within the broader disease setting of neurodegeneration. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating NAMPT, SIRT1 or the surrounding pathway space around not yet explicitly specified can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.60, novelty 0.75, feasibility 0.65, impact 0.68, mechanistic plausibility 0.70, and clinical relevance 0.00. ## Molecular and Cellular Rationale The nominated target genes are `NAMPT, SIRT1` and the pathway label is `not yet explicitly specified`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific. Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of NAMPT, SIRT1 or not yet explicitly specified is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. NAMPT-mediated NAD+ salvage pathways are critical for neuronal bioenergetics and protection after injury. Identifier 31553812. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. Ablation of NAMPT in dopaminergic neurons leads to neurodegeneration. Identifier 39489186. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage. Identifier 25215490. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 4. TREM2 receptor protects against complement-mediated synaptic loss by binding to complement C1Q. Identifier 37442133. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 5. Sirtuin-NAD Activator trial in AD (NCT05040321) using MIB-626 provides pathway-specific human validation. Identifier NCT05040321. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. SIRT1 has context-dependent roles in neuroinflammation, with some studies showing that excessive SIRT1 activation can impair protective immune responses. Identifier 27235851. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. NAMPT inhibitors are being explored as anticancer strategies, highlighting the pathway's role in cellular proliferation. Identifier 27235851. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 3. SIRT1 activators including resveratrol have failed to demonstrate consistent efficacy in human neurodegenerative disease trials. Identifier 27235851. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 4. NAMPT (visfastin) is elevated in metabolic syndrome and inflammation - raising question of whether enhancing already dysregulated pathway is optimal. Identifier 27235851. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.595`, debate count `1`, citations `9`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. 1. Trial context: ACTIVE_NOT_RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates NAMPT, SIRT1 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "NAMPT-SIRT1 Axis as Master Regulator of SASP-Dependent Complement Amplification". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting NAMPT, SIRT1 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers NAMPT, SIRT1 within the broader disease setting of neurodegeneration. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating NAMPT, SIRT1 or the surrounding pathway space around not yet explicitly specified can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.60, novelty 0.75, feasibility 0.65, impact 0.68, mechanistic plausibility 0.70, and clinical relevance 0.00.

Molecular and Cellular Rationale

The nominated target genes are `NAMPT, SIRT1` and the pathway label is `not yet explicitly specified`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific.
Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of NAMPT, SIRT1 or not yet explicitly specified is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

NAMPT-mediated NAD+ salvage pathways are critical for neuronal bioenergetics and protection after injury. Identifier 31553812. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Ablation of NAMPT in dopaminergic neurons leads to neurodegeneration. Identifier 39489186. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage. Identifier 25215490. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

TREM2 receptor protects against complement-mediated synaptic loss by binding to complement C1Q. Identifier 37442133. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Sirtuin-NAD Activator trial in AD (NCT05040321) using MIB-626 provides pathway-specific human validation. Identifier NCT05040321. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

SIRT1 has context-dependent roles in neuroinflammation, with some studies showing that excessive SIRT1 activation can impair protective immune responses. Identifier 27235851. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

NAMPT inhibitors are being explored as anticancer strategies, highlighting the pathway's role in cellular proliferation. Identifier 27235851. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

SIRT1 activators including resveratrol have failed to demonstrate consistent efficacy in human neurodegenerative disease trials. Identifier 27235851. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

NAMPT (visfastin) is elevated in metabolic syndrome and inflammation - raising question of whether enhancing already dysregulated pathway is optimal. Identifier 27235851. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.595`, debate count `1`, citations `9`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: ACTIVE_NOT_RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates NAMPT, SIRT1 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "NAMPT-SIRT1 Axis as Master Regulator of SASP-Dependent Complement Amplification".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting NAMPT, SIRT1 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["NAMPT-Mediated NAD+
Salvage Pathway"]
    B["SIRT1 Deacetylase
Activity Control"]
    C["NFKB1 Acetylation
Regulation"]
    D["SASP Cytokine Production
IL1B, TNFa, IL6"]
    E["C1Q/C3 Complement
Amplification Cascade"]
    F["Synaptic Loss
Mediated by Complement"]
    G["NAMPT Enhancement or
SIRT1 Activation"]
    H["SASP Suppression
Complement Cascade Blockade"]
    I["Neuroprotection
Synaptic Preservation"]
    A --> B
    B --> C
    C --> D
    D --> E
    E --> F
    G --> H
    H --> I
    style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style I fill:#1b5e20,stroke:#81c784,color:#81c784

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

9 citations 9 with PMID Validation: 0% 5 supporting / 4 opposing

✓ For (5)

No supporting evidence

No opposing evidence

(4) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 8CLIN 1GENE 0EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
NAMPT-mediated NAD+ salvage pathways are critical …	Supporting	MECH	-	-	-	-	PMID:31553812	-
Ablation of NAMPT in dopaminergic neurons leads to…	Supporting	MECH	-	-	-	-	PMID:39489186	-
P7C3 neuroprotective chemicals function by activat…	Supporting	MECH	-	-	-	-	PMID:25215490	-
TREM2 receptor protects against complement-mediate…	Supporting	MECH	-	-	-	-	PMID:37442133	-
Sirtuin-NAD Activator trial in AD (NCT05040321) us…	Supporting	MECH	-	-	-	-	PMID:NCT05040321	-
SIRT1 has context-dependent roles in neuroinflamma…	Opposing	MECH	-	-	-	-	PMID:27235851	-
NAMPT inhibitors are being explored as anticancer …	Opposing	MECH	-	-	-	-	PMID:27235851	-
SIRT1 activators including resveratrol have failed…	Opposing	CLIN	-	-	-	-	PMID:27235851	-
NAMPT (visfastin) is elevated in metabolic syndrom…	Opposing	MECH	-	-	-	-	PMID:27235851	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 5

NAMPT-mediated NAD+ salvage pathways are critical for neuronal bioenergetics and protection after injury

PMID:31553812

Ablation of NAMPT in dopaminergic neurons leads to neurodegeneration

PMID:39489186

P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage

PMID:25215490

TREM2 receptor protects against complement-mediated synaptic loss by binding to complement C1Q

PMID:37442133

Sirtuin-NAD Activator trial in AD (NCT05040321) using MIB-626 provides pathway-specific human validation

PMID:NCT05040321

✗ Opposing Evidence 4

SIRT1 has context-dependent roles in neuroinflammation, with some studies showing that excessive SIRT1 activat…▼

SIRT1 has context-dependent roles in neuroinflammation, with some studies showing that excessive SIRT1 activation can impair protective immune responses

PMID:27235851

NAMPT inhibitors are being explored as anticancer strategies, highlighting the pathway's role in cellular prol…▼

NAMPT inhibitors are being explored as anticancer strategies, highlighting the pathway's role in cellular proliferation

PMID:27235851

SIRT1 activators including resveratrol have failed to demonstrate consistent efficacy in human neurodegenerati…▼

SIRT1 activators including resveratrol have failed to demonstrate consistent efficacy in human neurodegenerative disease trials

PMID:27235851

NAMPT (visfastin) is elevated in metabolic syndrome and inflammation - raising question of whether enhancing a…▼

NAMPT (visfastin) is elevated in metabolic syndrome and inflammation - raising question of whether enhancing already dysregulated pathway is optimal

PMID:27235851

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-16 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Novel Therapeutic Hypotheses for Neurodegeneration

Hypothesis 1: ID2-Mediated PV Repression as a Convergence Point for Metabolic and Transcriptional Dysfunction

Description: Inhibitor of DNA binding 2 (ID2) is upregulated in Alzheimer's disease and directly represses parvalbumin (PVALB) transcription while simultaneously impairing mitochondrial biogenesis through inhibition of PGC-1α. Targeting ID2 could dual-rescue PV interneuron identity and metabolic capacity.

Target Gene/Protein: ID2 (Inhibitor of DNA Binding 2)

Supporting Evidence: ID2 overexpression in GABAergic pr

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

ID2-mediated PV repression

Weaknesses: The chain `AD -> ID2 up -> PV loss + PGC-1α suppression -> PV dysfunction` is mostly stitched from developmental or non-AD data, not direct adult AD PV-interneuron causality. The key gap is cell-type specificity: adult PV dysfunction in AD has not been shown to be driven by ID2 in vivo.
Counter-evidence: PGC-1α itself is reduced in AD brain, but that does not identify ID2 as the upstream cause ([PMID:19273754](https://pubmed.ncbi.nlm.nih.gov/19273754/)). AD-linked APP/AICD signaling can also increase PGC-1α expression, arguing against

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Drug Development Feasibility Assessment: Neurodegeneration Hypotheses

Executive Summary

Of the seven hypotheses, PARP1 and C3 complement pathway have the clearest path to pharmacological exploitation. The remaining five have target validation, chemical matter, or cell-type delivery challenges that make them high-risk near-term bets. Below is a systematic breakdown.

1. PARP1 Hyperactivation → NAD+ Depletion

Druggability: High

PARP1 is one of the most tractable targets in all of these hypotheses. It has an established enzymatic function (poly(ADP-ribosyl)ation

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

Price History

7d Trend

↔

Stable

7d Momentum

▲ 0.9%

Volatility

High

0.0560

Events (7d)

⚡ Price Movement Log Recent 12 events

	Event	Price	Change	Source	Time
💬	Debate Round	$0.568	▼ 13.8%	market_dynamics	2026-04-17 08:49
💬	Debate Round	$0.659	▲ 8.9%	market_dynamics	2026-04-17 08:27
📊	Score Update	$0.606	▼ 5.2%	market_dynamics	2026-04-17 07:36
💬	Debate Round	$0.638	▲ 4.7%	market_dynamics	2026-04-17 06:50
📄	New Evidence	$0.610	▼ 10.9%	market_dynamics	2026-04-17 05:45
📊	Score Update	$0.684	▲ 10.4%	market_dynamics	2026-04-17 05:32
📄	New Evidence	$0.620	▲ 3.1%	market_dynamics	2026-04-17 04:08
📊	Score Update	$0.601	▼ 3.3%	market_dynamics	2026-04-17 02:27
📄	New Evidence	$0.621	▲ 4.2%	market_dynamics	2026-04-16 23:40
📄	New Evidence	$0.596	▼ 8.3%	evidence_update	2026-04-16 21:09
📄	New Evidence	$0.650	▲ 10.1%	evidence_update	2026-04-16 21:09
✨	Listed	$0.590		post_process	2026-04-16 21:09

Clinical Trials (1)

0
Active

0
Completed

22
Total Enrolled

PHASE1
Highest Phase

Sirtuin-NAD Activator in Alzheimer's Disease PHASE1

ACTIVE_NOT_RECRUITING · NCT05040321 · Brigham and Women's Hospital

22 enrolled · 2021-12-01 · → 2025-12-15

Alzheimer's Disease (Incl Subtypes) Dementia

MIB-626 Placebo

📚 Cited Papers (6)

P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage.

Cell (2014) · PMID:25215490

No extracted figures yet

Keeping the senescence secretome under control: Molecular reins on the senescence-associated secretory phenotype.

Experimental gerontology (2017) · PMID:27235851

No extracted figures yet

Subcellular NAMPT-mediated NAD<sup>+</sup> salvage pathways and their roles in bioenergetics and neuronal protection after ischemic injury.

Journal of neurochemistry (2020) · PMID:31553812

No extracted figures yet

TREM2 receptor protects against complement-mediated synaptic loss by binding to complement C1q during neurodegeneration.

Immunity (2023) · PMID:37442133

No extracted figures yet

Ablation of NAMPT in dopaminergic neurons leads to neurodegeneration and induces Parkinson's disease in mouse.

Brain research bulletin (2024) · PMID:39489186

No extracted figures yet

Paper:NCT05040321

No extracted figures yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (0)

No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.

⚔ Arena Performance

Elo Rating

1549 ±290

Record

1W / 0L / 0D

1 matches

Full Lineage ➔

→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Low Efficiency Resource Efficiency Score

0.00

7.2th percentile (776 hypotheses)

Tokens Used

14,167

KG Edges Generated

Citations Produced

Cost Ratios

Cost per KG Edge

7083.50 tokens

Lower is better (baseline: 2000)

Cost per Citation

1574.11 tokens

Lower is better (baseline: 1000)

Cost per Score Point

24052.63 tokens

Tokens / composite_score

Score Impact

Efficiency Boost to Composite

+0.000

10% weight of efficiency score

Adjusted Composite

0.592

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for NAMPT, SIRT1.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for NAMPT, SIRT1 →

Loading history…

⚖️ Governance History

No governance decisions recorded for this hypothesis.

Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

Browse all governance decisions →

KG Entities (3)

NAMPT, SIRT1 SIRT3, PVALB neurodegeneration

Related Hypotheses

Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration

Score: 0.907 | neurodegeneration

Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Collapse

Score: 0.895 | neurodegeneration

SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence

Score: 0.893 | neurodegeneration

TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegeneration

Score: 0.892 | neurodegeneration

Optimized Temporal Window for Metabolic Boosting Therapy Determines Success of Microglial State Transition Restoration

Score: 0.887 | neurodegeneration

Estimated Development

Estimated Cost

Timeline

0 months

🧪 Falsifiable Predictions (2)

2 total 0 confirmed 0 falsified

IF we orally administer nicotinamide riboside (NR, 400mg/kg/day via drinking water for 8 weeks) to 3xTg Alzheimer's disease mice starting at 6 months of age, THEN we will observe statistically significant elevations in hippocampal NAD+ levels (≥50% vs. vehicle), increased SIRT1 deacetylase activity (≥30% vs. vehicle), decreased nuclear NFKB1 acetylation (≥40% vs. vehicle), reduced hippocampal IL1B protein (≥50% vs. vehicle), decreased complement C1Q mRNA/protein (≥40% vs. vehicle), decreased C3 mRNA/protein (≥40% vs. vehicle), and preserved synaptic density (≥30% increase in PSD95+ puncta vs. vehicle) within the 8-week timeframe.

pending conf: 0.62

Expected outcome: Increased NAMPT-mediated NAD+ salvage will activate SIRT1, suppress NFKB1-driven SASP, reduce complement C1Q/C3 amplification, and prevent synaptic loss in a mouse neurodegeneration model.

Falsified by: NR treatment fails to increase hippocampal NAD+ by ≥50% AND fails to increase SIRT1 activity by ≥30% AND complement C1Q or C3 protein levels increase or remain unchanged (≤10% decrease) AND PSD95+ synaptic puncta show no preservation (≤10% increase) or decrease, OR synaptic loss progresses at the same rate as vehicle-treated mice.

Method: 3xTg AD mice (n=15-20 per group, 6-month-old males, randomized to NR vs. vehicle); hippocampal NAD+ measurement by enzymatic cycling assay, SIRT1 activity by fluorometric deacetylase assay, NFKB1 acetylation by immunoprecipitation-Western blot, IL1B/C1Q/C3 by ELISA and qPCR, synaptic density by confocal microscopy of PSD95+ and synaptophysin+ puncta in CA1 stratum radiatum; endpoints at 8 weeks.

IF we apply SRT2104 (SIRT1 activator, 100mg/kg/day oral gavage for 4 weeks) to 5xFAD mice at 4 months of age, THEN we will observe decreased NFKB1 acetylation in cortical neurons (≥50% vs. vehicle), reduced IL1B and CXCL1 secretion from iPSC-derived astrocytes co-cultured with 5xFAD neurons (≥40% vs. vehicle), decreased C1Q and C3 secretion in astrocyte-neuron co-culture conditioned media (≥40% vs. vehicle), reduced complement C3 deposition at synapses (≥50% vs. vehicle), and improved synaptic integrity as measured by increased mEPSC frequency (≥30% vs. vehicle) within the 4-week timeframe.

pending conf: 0.58

Expected outcome: Direct SIRT1 activation will suppress NFKB1 acetylation and SASP cytokine production, reducing complement C1Q/C3 amplification and protecting synapses in a mouse and human iPSC co-culture neurodegeneration model.

Falsified by: SRT2104 treatment fails to decrease NFKB1 acetylation by ≥50% in cortical neurons AND SASP cytokines (IL1B, CXCL1) show ≤20% decrease or increase in conditioned media AND C1Q or C3 protein in conditioned media increases or decreases by <30% AND complement C3 deposition at synapses does not decrease by ≥50% AND mEPSC frequency shows ≤10% improvement or deterioration, OR synapse loss continues at vehicle-equivalent rates.

Method: 5xFAD mice (n=12-15 per group, 4-month-old females, randomized to SRT2104 vs. vehicle) plus transwell co-cultures of iPSC-derived cortical neurons (AD patient lines, n=3 lines) and iPSC-derived astrocytes (n=3 lines) treated with SRT2104 (1μM) or vehicle for 7 days; endpoints include nuclear NFKB1 acetylation (ImageStream), IL1B/CXCL1 ELISA of conditioned media, C1Q/C3 ELISA, C3 immunostaining at PSD95+ synapses, and whole-cell patch clamp mEPSC recordings.

Knowledge Subgraph (2 edges)

promoted: Ketone-Based Metabolic Switching to Restore PV Interneuron Function (1)

SIRT3, PVALB→neurodegeneration

promoted: NAMPT-SIRT1 Axis as Master Regulator of SASP-Dependent Complement Amplification (1)

NAMPT, SIRT1→neurodegeneration

Predicted Protein Structure

🔮 NAMPT — AlphaFold Prediction C9JF35 Click to expand 3D viewer

AI-predicted structure from AlphaFold | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

test

neurodegeneration | 2026-04-16 | archived

Community Feedback

0 0 upvotes · 0 downvotes

💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Same Analysis (1)

Ketone-Based Metabolic Switching to Restore PV Interneuron Function

Score: 0.61 · SIRT3, PVALB

→ View all analysis hypotheses

NAMPT-SIRT1 Axis as Master Regulator of SASP-Dependent Complement Amplification

Description

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

Curated Mechanism Pathway

Dimension Scores

✓ Supporting Evidence 5

✗ Opposing Evidence 4

Novel Therapeutic Hypotheses for Neurodegeneration

Hypothesis 1: ID2-Mediated PV Repression as a Convergence Point for Metabolic and Transcriptional Dysfunction

Drug Development Feasibility Assessment: Neurodegeneration Hypotheses

Executive Summary

1. PARP1 Hyperactivation → NAD+ Depletion

Druggability: High

Price History

Clinical Trials (1)

📚 Cited Papers (6)

📅 Citation Freshness Audit

📙 Related Wiki Pages (0)

📓 Linked Notebooks (0)

⚔ Arena Performance

🔄 Related Hypotheses

Same Analysis (1)

🧬 Same Target Gene / Disease (30)

📊 Resource Economics & ROI

Cost Ratios

Score Impact

How Economics Pricing Works

📋 Reviews View all →

💬 Discussion

⚖️ Governance History

KG Entities (3)

Related Hypotheses

Estimated Development

🧪 Falsifiable Predictions (2)

Knowledge Subgraph (2 edges)

promoted: Ketone-Based Metabolic Switching to Restore PV Interneuron Function (1)

promoted: NAMPT-SIRT1 Axis as Master Regulator of SASP-Dependent Complement Amplification (1)

Predicted Protein Structure

Source Analysis

test

Community Feedback

Same Analysis (1)